新辅助放化疗治疗直肠癌患者的临床效果及其安全性分析

Clinical Effect and Safety Analysis of Neoadjuvant Chemoradiotherapy for Rectal Cancer

目的:探讨新辅助放化疗治疗直肠癌患者的临床效果及其安全性分析。方法:福建医科大学附属肿瘤医院2019年2月-2021年2月确诊的直肠癌患者165例,根据随机数字表法将其分为对照组和观察组,其中对照组80例,行常规直肠癌根治术治疗;观察组85例,术前采用新辅助放化疗后再行直肠癌根治术。观察两组患者术后的临床疗效,比较两组患者的生活质量,分析两组患者的不良反应发生率。结果:观察组完全缓解率(complete response,CR)为45.88%,临床总有效率为85.88%,均高于对照组的25.00%、72.50%,差异均有统计学意义(P<0.05)。术后1周,观察组患者的生理职能、生理机能、社会功能、健康状况、躯体疼痛、精力、精神健康、情感职能评分均高于对照组患者,差异均有统计学意义(P<0.05)。观察组患者术后1个月不良反应总发生率为3.53%,低于对照组患者的15.00%,差异有统计学意义(P<0.05)。结论:新辅助放化疗可明显提高患者的生活质量评分,改善患者的临床疗效,且并发症较少,安全性较高,值得在临床上推广应用。

Objective:To explore the clinical effect and safety of neoadjuvant chemoradiotherapy in the treatment of rectal cancer.Method:A total of 165 patients with rectal cancer diagnosed in Cancer Hospital Affiliated to Fujian Medical University from February 2019 to February 2021 were selected.They were divided into control group and observation group according to the random number table method.Among them,80 patients with rectal cancer in the control group were treated with routine radical resection of rectal cancer;85 patients with rectal cancer in the observation group were treated with neoadjuvant chemoradiotherapy before radical resection of rectal cancer.The clinical efficacy of the two groups was observed,the quality of life of the two groups was compared,and the incidence of adverse reactions of the two groups were analyzed.Result:The complete response (CR) rate of patients in the observation group was 45.88%,and the total clinical effective rate was 85.88%,which were higher than 25.00% and 72.50% of patients in the control group (P<0.05).After operation of 1 week,the scores of physiological function,physiological function,social function,health status,physical pain,energy,mental health and emotional function in the observation group were higher than those in the control group,and the differences were statistically significant (P<0.05).The total incidence of adverse reactions after operation of 1 month in the observation group was 3.53%,lower than 15.00% in the control group (P<0.05).Conclusion:Neoadjuvant chemoradiotherapy can significantly improve the quality of life score of patients and improve the clinical efficacy of patients,with fewer complications and higher safety,which is worthy of clinical application.